Skip to main content

Table 2 Serum albumin trends at 2 months after chemotherapy

From: Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy

 

Well-nourished (n = 69)

Bad-nourished (n = 39)

p value

Age (median, range)

63 (34–83)

66 (36–80)

0.67

Gender (male)

38

20

0.7

WHO performance status (> 2)

6 (8.7%)

11 (28.2)

< 0.01

Body mass index (median, range)

24.1 (18.6–33.8)

23.1 (13.3–28.8)

0.47

Primary site

 Rectum

23

10

0.4

 Right-sided (n = 51)

27

24

0.03

 Left-sided (n = 57)

40

17

0.15

Residual of primary tumor

12

5

0.53

First line regimen

 FOLFOX/FOLFIRI

19/56

11/22

0.94

Add-on targeting agent

 VEGFR (n = 41)

30 (43.5%)

11 (28.2%)

0.11

 EGFR (n = 38)

26 (37.7%)

12 (30.8%)

0.47

 None (n = 29)

13 (18.8%)

16 (41.0%)

0.01

Adverse eventa

 Hematotoxicity

  Grade 2

13 (18.8%)

12 (30.8%)

0.11

  Grade 3

4 (5.8%)

4 (10.3%)

0.39

  Grade 4

0 (0%)

1 (2.6%)

0.18

 Non-hematotoxicity

  Grade 2

11 (15.9%)

15 (38.5%)

< 0.01

  Grade 3

7 (10.1%)

6 (15.4%)

0.42

  Grade 4

1 (1.4%)

0 (0%)

0.68

Tumor markerb

 CEA

16.8 (3.7–45.1)

6.9 (2.9–14.4)

0.39

 CA19-9

19.6 (2.3–46.9)

15.6 (6.9–81.2)

0.19

  1. aAccording to the CTC-AE Ver5.0
  2. bMedian with internal quadorant range